Thông tin thuốc của Granisetron

Thông tin này không áp dụng cho tất cả các quốc gia. Vui lòng tham khảo thông tin kê toa lưu hành tại Việt Nam.

Thông tin thuốc gốc

Chỉ định và Liều dùng

Intravenous
Treatment and prophylaxis of postoperative nausea and vomiting

Adult: 1 mg over 30 sec, to be given before induction of anaesth. May be repeated up to max of 3 mg in 24 hr.

Intravenous
Nausea and vomiting associated with cancer chemotherapy

Adult: 1-3 mg 5 min prior to start of chemotherapy, by infusion over 5 min or by bolus inj over at least 30 sec. Further doses may be given at least 10 min apart. Max: 9 mg daily.
Child: 2-16 yr 10-40 mcg/kg (max: 3,000 mcg) by infusion over 5 min to be given prior to start of chemotherapy. An additional dose may be given w/in 24 hr, at least 10 min after the 1st infusion.

Intravenous
Prophylaxis of nausea and vomiting associated with radiation therapy

Adult: 1-3 mg 5 min prior to start of radiotherapy, by infusion over 5 min or by bolus inj over at least 30 sec. Further doses may be given at least 10 min apart. Max: 9 mg daily.

Oral
Nausea and vomiting associated with cancer chemotherapy

Adult: 1-2 mg w/in 1 hr prior to start of chemotherapy, then 2 mg daily as a single or in 2 divided doses for up to 1 wk after chemotherapy. Max: 9 mg daily.

Oral
Prophylaxis of nausea and vomiting associated with radiation therapy

Adult: 2 mg once daily w/in 1 hr of irradiation.

Transdermal
Nausea and vomiting associated with cancer chemotherapy

Adult: As patch releasing 3.1 mg/24 hr: Apply 1 patch at the upper arm 24-48 hr prior to chemotherapy; remove at least 24 hr after the end of chemotherapy. May be worn for up to 7 days depending on the duration of the chemotherapy regimen.

Cách dùng

May be taken with or without food.

Hướng dẫn pha thuốc

IV infusion: Dilute in dextrose 5% or NaCl 0.9% inj to a total vol of 20-50 mL.

Tương kỵ

Y-site: Amphotericin B. Syringe: Ceftriaxone.

Thận trọng

Patient w/ cardiac co-morbidities, on cardiotoxic chemotherapy and/or w/ concomitant electrolyte abnormalities. May mask progressive ileus and/or gastric distention. Childn. Pregnancy and lactation.

Tác dụng không mong muốn

Headache, insomnia, constipation, diarrhoea, elevated hepatic transaminases; QT prolongation; bradycardia, palpitations, sick sinus syndrome, chest pain. Application site reactions (transdermal): Rash, pain, erythema, pruritus, irritation, burn, vesicles, urticaria, discolouration; patch non-adhesion.

Phân loại thai kỳ (US FDA)

IV/Parenteral/PO/SC/Transdermal: B

Thông tin tư vấn bệnh nhân

Avoid prolonged exposure to heat (transdermal patch).

Chỉ số theo dõi

Monitor for signs of subacute intestinal obstruction; ECG and clinical abnormalities.

Quá liều

Symptoms: Mild headache. Management: Symptomatic treatment.

Tương tác

Induced metabolism w/ phenobarbital. Risk of serotonin syndrome w/ other serotonergic agents e.g. SSRIs, and serotonin and norepinephrine reuptake inhibitors (SNRIs). Altered clearance w/ CYP enzyme inducers or inhibitors. Concomitant use w/ drugs known to prolong QT interval may result in clinical consequences.

Tác dụng

Description:
Mechanism of Action: Granisetron is a highly selective 5-HT₃-receptor antagonist w/ little or no affinity for other serotonin receptors. It blocks serotonin peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone.
Duration: Up to 24 hr.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Bioavailability: Approx 60%. Time to peak plasma concentration: Approx 2 hr.
Distribution: Widely distributed throughout the body. Volume of distribution: Approx 3 L/kg. Plasma protein binding: Approx 65%.
Metabolism: Hepatically metabolised via N-demethylation and aromatic ring oxidation followed by conjugation.
Excretion: Via urine (<20% as unchanged drug), and the remainder in the urine and faeces (as metabolites). Elimination half-life: 6 hr (oral); approx 9 hr (IV).

Đặc tính

Chemical Structure Image — **Granisetron**

Bảo quản

Tab/oral soln/inj: Store between 15-30°C. Protect from light. Patch: Store between 20-25°C.

Phân loại MIMS

Thuốc chống nôn / Trị liệu chăm sóc nâng đỡ

Phân loại ATC

A04AA02 - granisetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.

Tài liệu tham khảo

Anon. Granisetron. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 26/10/2015.

Buckingham R (ed). Granisetron. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com/mc/martindale/2009/ms-3385-h.htm. Accessed 26/10/2015.

Granisetron Hydrochloride Injection, Solution (Fresenius Kabi USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 26/10/2015.

Granisetron hydrochloride Tablet (Ascend Laboratories, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 26/10/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Granisetron hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 26/10/2015.

Sancuso. U.S. FDA. https://www.fda.gov/. Accessed 26/10/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Granisetron từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com